Physician profile
Francesca Locklear Carter
NPI 1972032993
$1,894.27
in general payments reported to CMS, 2019-2025
14 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $193 · 2022: $1,066 · 2023: $486 · 2024: $23.05 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $426.20 | 2022-2023 | |
| Alkermes, INC. | $343.04 | 2021-2025 | Aristada, Vivitrol, Lybalvi |
| Abbvie INC. | $273.29 | 2021-2022 | |
| Axsome Therapeutics, INC. | $163.50 | 2022-2023 | Auvelity |
| Supernus Pharmaceuticals, INC. | $132.57 | 2022-2023 | Qelbree |
| Lundbeck LLC | $109.49 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $102.60 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $91.45 | 2022-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $57.05 | 2021-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $52.08 | 2022-2023 | Quviviq |
| Bausch Health US, LLC | $37.76 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $37.72 | 2022-2023 | Austedo |
| Corium, LLC | $34.55 | 2022 | |
| Neos Therapeutics, LP | $32.97 | 2022-2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francesca Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.